Therapeutic Targets for Bone and Soft-Tissue Sarcomas.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest. 15. Biomed Eng Online. 2021 Mar 2;20(1):24. doi: 10.1186/s12938-021-00860-0. Osteosarcoma: a review of current and future therapeutic approaches. Zhao X(#)(1), Wu Q(#)(2), Gong X(3), Liu J(2), Ma Y(2). Author information: (1)Anhui Chest Hospital, 397 Jixi Road, Hefei, 230022, China. (2)Materials Genome Institute, Shanghai University, Shanghai, 201800, China. (3)Materials Genome Institute, Shanghai University, Shanghai, 201800, China. gongxiuqing@shu.edu.cn. (#)Contributed equally Osteosarcoma (OS) is the most common primary bone malignancy that affects children and young adults. OS is characterized by a high degree of malignancy, strong invasiveness, rapid disease progression, and extremely high mortality rate; it is considered as a serious threat to the human health globally. The incidence of OS is common in the metaphysis of long tubular bones, but rare in the spine, pelvis, and sacrum areas; moreover, majority of the OS patients present with only a single lesion. OS has a bimodal distribution pattern, that is, its incidence peaks in the second decade of life and in late adulthood. We examine historical and current literature to present a succinct review of OS. In this review, we have discussed the types, clinical diagnosis, and modern and future treatment methods of OS. The purpose of this article is to inspire new ideas to develop more effective therapeutic options. DOI: 10.1186/s12938-021-00860-0 PMCID: PMC7923306